Pfizer to Acquire Trillium Therapeutics for $2.26B; Completes Acquisition for $2.22B
Pfizer Inc. entered into a definitive agreement to acquire fellow public firm Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative cancer therapies.
- Large Molecule
- Full Acquisition
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com